Skip to content

Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing

Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With Three-dimensional Printing Secondary IDs:

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04929197
Acronym
PERSBRA
Enrollment
50
Registered
2021-06-18
Start date
2016-04-21
Completion date
2023-11-01
Last updated
2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Neoplasms, Left Sided Breast Cancer

Brief summary

Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence. However, significant portions of the heart and the lungs are exposed to low dose radiation during radiotherapy, which result in stochastic side effects among breast cancer survivors. Inspired by 3D printing technology, we approached this issue with an in-house made PERSonalized BReAst holder system (PERSBRA). PERSBRA is composed of a 3D-printed plastic holder covering the whole breast and an air-filled interface. Its main function is to reproducibly adjust the breast position to decrease heart and lung radiation exposure in tangential fields. Here we propose to measure the performance of PERSBR in terms of radiation dosimetry in 50 patients receiving scheduled whole breast irradiation. For customized PERSBRA, body shape of the patient with or without a bustier corset will be captured with a handheld 3D scanner and input into a 3D printer for PERSBRA design and manufacturing. A participant will receive two more CT scans in addition to the simulation scan with PERSBRA in place before the first and the sixth fractions of irradiation. These images will be analyzed for dosimetric parameters in the presence/absence of PERSBRA as well as position reproducibility. The data will provide proof-of-principle evidence for the clinical utility of PERSBRA and will facilitate its further refinement.

Detailed description

1. Patients with early breast cancer or ductal carcinoma in situ treated with breast conservation surgery. 2. Adjuvant radiotherapy to the breast is part of the patient's initial treatment plan. 3. Non-contrast CT scan is a routine procedure for the patient's radiotherapy treatment planning.

Interventions

DEVICEPERSBRA

After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA. PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA.

Sponsors

Taipei Medical University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Patients with early breast cancer or carcinoma in situ after partial mastectomy have decided to receive adjuvant radiation therapy for the breast on the affected side, and use non-contrast computed tomography to obtain localized images is part of the original treatment plan.

Exclusion criteria

* Clinical diagnosis or pathological diagnosis has lymph node metastasis, lymph node micrometastasis, or lymph node tumor cells. * The clinical diagnosis is likely to have metastatic cancer. * Pregnant women. * Be younger than 20 years old. * The subject was unable to read and understand the subject consent form written in Chinese and complete the informed consent procedure.

Design outcomes

Primary

MeasureTime frameDescription
Irradiated cardiac doseTime Frame: At simulation, expected average of 1 weekRadiation dose distribution of the cardiopulmonary on the affected side.

Secondary

MeasureTime frameDescription
Irradiated dose of axillary lymphatic areaAt simulation, expected average of 1 weekIrradiated dose of axillary lymphatic area.
Clinical target volumeAt simulation, expected average of 1 weekRadiation dose distribution of clinical target volume.
Irradiated dose of left anterior descending arteryTime Frame: At simulation, expected average of 1 weekRadiation dose distribution of the left anterior descending artery on the affected side.
Irradiated lung doseAt simulation, expected average of 1 weekRadiation dose distribution of the lung on the affected side.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026